With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK charity behind the popular Dry January initiative, found that 30% of men and 26% of women in the UK wished to reduce the amount of alcohol they drank in 2024.
In 2023, the World Health Organization (WHO) published a statement in that 鈥渨hen it comes to alcohol consumption, there is no safe amount that does not affect health鈥�. More recently, the US surgeon general advised that alcohol bottles should feature cancer warnings on their labels, akin to tobacco products, as a way to 鈥渋ncrease awareness of alcohol鈥檚 cancer risk and minimise harm鈥�.
Research by Gallup , with young adults in the US becoming progressively less likely to use alcohol over the past two decades. However, while the realities of alcohol鈥檚 effect on health may be prompting younger individuals to take note, research by the US National Institute of Alcohol Abuse & Alcoholism (NIAAA) indicates there are with alcohol use disorder (AUD).
Three US Food and Drug Administration (FDA)-approved medications for AUD currently exist, and glucagon-like peptide 1 receptor agonists (GLP 1RAs), popularly known for their use in obesity and diabetes, are now being studied as potential medications. Yet research by US non-profit the Federation of American Scientists (FAS) indicates they are only prescribed to around
The treatment ideal for alcohol use disorder
The FDA approved the first AUD medication, Antabuse (disulfiram), in 1951 and the second approval came after a gap of more than 40 years, for naltrexone sold as Revia/Vivitrol, now commonly known as a treatment for opioid use disorder. This was followed by the Campral (acamprosate) approval in 2004.
Dr Akhil Anand, a psychiatrist at the Cleveland Clinic, says the available AUD medications are efficacious, but mainly as preventatives towards harmful drinking and binge drinking.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淭hese medications may not completely solve abstinence, but they definitely will help a patient in some capacity,鈥� he says.
“Ideally, treatment would be a combination of an intensive outpatient or residential programme and also pharmacotherapy.”
Increased awareness of the broad spectrum of treatment options for AUD could enhance their utilisation, but Dr Lorenzo Leggio, clinical director of the National Institute on Drug Abuse (NIDA), emphasises that treatment should not be viewed as rehab versus medication.
He adds that both approaches are important, but the most appropriate treatment option(s) depends on factors including the severity of AUD, and the presence of medical and mental health comorbidities.
鈥淚n general, it鈥檚 important to keep in mind that AUD is a chronic relapsing but treatable condition and as such, it鈥檚 important to establish long-term patient care plans,鈥� Leggio concludes.
The roots of treatment underutilisation
Despite the apparent efficacy of AUD medications, various factors have influenced their underutilisation.
Firstly, a historic lack of addiction-related education among healthcare providers has presented a significant primary hurdle towards their prescription.
鈥淸This] is now improved drastically, but with a lot of medical school training, addiction isn’t the core topic, and if you don鈥檛 prescribe AUD medications during your residency, it鈥檚 very unlikely you鈥檙e going to prescribe them in clinical practice,鈥� says Anand.
This issue is further exacerbated by the fact that those who may benefit from treatment often don鈥檛 come asking for it, and some family doctors may feel some hesitation in prescribing these medications, due to a lack of training.
Secondly, some providers may worry about alcohol withdrawal syndrome (AWS). 鈥淭hat complicates the picture鈥�. and makes these medications a bit more difficult to just pick up and start using,鈥� says Dr Niranjan Karnik, professor of psychiatry and co-director of the Institute for Research on Addictions at the University of Illinois, Chicago.
Characterised by symptoms such as anxiety, shakiness, and vomiting, AWS may occur when an individual stops drinking alcohol. More severe symptoms can include seizures and delirium tremens, which can prove fatal.
GLP-1 agonists could play a role
A recent report concluded that GLP-1s may be effective in the treatment of AUD and that randomised clinical trials are 鈥渦rgently needed鈥� to confirm whether GLP-1 agonists could be used to treat AUD and substance use disorders (SUDs).
Since primary care providers are now comfortable working with these weight loss medications, trying to use them for alcohol reduction and weight loss would be appealing to them, says Karnik. The use of such drugs may also change the dynamic around patient interaction.
Karnik adds: 鈥淲ith alcohol use鈥�..patients usually have to be at that hard tipping point where they have had some particularly negative consequences before they’re going to come in and ask for a treatment.鈥�
Multi-disciplinary approach that targets stigma
鈥淪tigma can impact a person鈥檚 willingness to seek treatment, as can bias among treatment providers,鈥� says Leggio.
To remove this stigma, Anand states that societal changes are needed when thinking about substance use disorders.
He adds: 鈥淪ociety looks down on people that have substance use disorders, so folks that have substance use disorders isolate. They’re ambivalent. They try to avoid addressing it.鈥�
Treatment approaches to AUD may be flawed since they largely reside in the domain of addiction specialists.
Anand explains: 鈥淎 liver doctor will not care about the addiction until the person develops alcohol cirrhosis. I think we need to be more interdisciplinary and multi-disciplinary when it comes to substance use disorders.鈥�
With a more multi-disciplinary approach, he states it may help to give patients more offramps before their AUD becomes severe: 鈥淚n the US, we’re not a preventative society; our hospital systems are to treat disease states, but we’re not really designed to address prevention, and that’s a big problem.鈥�
How the Trump administration may approach AUD
With Trump back in the White House, many are adopting a 鈥渨ait and see approach鈥� to gauge potential change in the healthcare sector. Kyle Faget, partner at law firm Foley & Lardner concedes that it is hard to say what the new administration will mean for addiction treatment, but the new administration is expected to take a tougher stance and more punitive approach to drugs and drug trafficking.
Still, Anand is optimistic, noting there has generally been a mutual interest from Democrats and Republicans in tackling addiction.
鈥淟ast time he [Trump] was president, he did a lot of good things for suboxone in relation to the opioid epidemic,鈥� he notes.
In addition, Faget observes that neither Trump nor Robert F Kennedy Jr., the likely secretary of the Department of Health and Human Services, drink alcohol. Still, warning labels on alcohol containers 鈥渟eems unlikely鈥� because the Trump administration will favour 鈥渓ess and not more regulation鈥�.
Conversely, Karnik states the new administration鈥檚 approach to AUD may come from more of a prohibitionist standpoint: 鈥淭hey aren’t [Trump and RFK Jr] very sympathetic to harm reduction practices, which, for alcohol, are proven right.
“Even though the surgeon general said that there is no lower threshold of safety, clearly drinking one opposed to two drinks a day is a marked change in terms of an individual鈥檚 health risk over time.
鈥淏ut those approaches are not going to be supported by this administration, is my guess.鈥�
